{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T12:30:17Z","timestamp":1748521817087,"version":"3.37.3"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Tara Miller Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>For patients with melanoma, gastrointestinal immune-related adverse events are common after receipt of anti-CTLA4 therapy. These present difficult decision points regarding whether to discontinue therapy. Detailing the situations in which colitis might predict for improved survival and how this is affected by discontinuation or resumption of therapy can help guide clinical decision-making.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Patients with stage IV melanoma receiving anti-CTLA4 therapy from 2008 to 2019 were analyzed. Immune-related colitis treated with \u226550 mg prednisone or equivalent daily or secondary immunosuppression was included. Moderate colitis was defined as receipt of oral glucocorticoids only; severe colitis was defined as requiring intravenous glucocorticoids or secondary immunosuppression. The primary outcome was overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 171 patients received monotherapy, and 91 received dual checkpoint therapy. In the monotherapy group, 25 patients developed colitis and a nonsignificant trend toward improved OS was observed in this group. Notably, when colitis was categorized as none, moderate or severe, OS was significantly improved for moderate colitis only. This survival difference was not present after dual checkpoint therapy. There were no differences in known prognostic variables between groups, and on multivariable analysis neither completion of all ipilimumab cycles nor resumption of immunotherapy correlated with OS, while the development of moderate colitis did significantly affect OS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This single-institution retrospective series suggests moderate colitis correlates with improved OS for patients with stage IV melanoma treated with single-agent anti-CTLA4, but not dual agent, and that this is true regardless of whether the immune-checkpoint blockade is permanently discontinued.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac108","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T15:02:10Z","timestamp":1654527730000},"page":"799-808","source":"Crossref","is-referenced-by-count":4,"title":["Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8426-6540","authenticated-orcid":false,"given":"Emily J","family":"Anstadt","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0803-5529","authenticated-orcid":false,"given":"Brian","family":"Chu","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Yegya-Raman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Doucette","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra","family":"Poirier","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahan J","family":"Mohiuddin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Maity","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9563-297X","authenticated-orcid":false,"given":"Andrea","family":"Facciabene","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi K","family":"Amaravadi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgos C","family":"Karakousis","sequence":"additional","affiliation":[{"name":"Division of Endocrine and Oncologic Surgery, Department of Surgery, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine V","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara C","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn M","family":"Schuchter","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John N","family":"Lukens","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pennsylvania , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"2022090215583548600_CIT0001","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"2022090215583548600_CIT0002","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer","volume":"19","author":"Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2022090215583548600_CIT0003","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022090215583548600_CIT0004","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1200\/JCO.2016.34.15_suppl.3047","article-title":"Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab","volume":"34","author":"Mian","year":"2016","journal-title":"J Clin Oncol"},{"key":"2022090215583548600_CIT0005","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022090215583548600_CIT0006","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022090215583548600_CIT0007","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"2022090215583548600_CIT0008","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022090215583548600_CIT0009","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022090215583548600_CIT0010","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022090215583548600_CIT0011","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2022090215583548600_CIT0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2022090215583548600_CIT0013","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2022090215583548600_CIT0014","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"2022090215583548600_CIT0015","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"key":"2022090215583548600_CIT0016","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2022090215583548600_CIT0017","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022090215583548600_CIT0018","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00262-019-02303-1","article-title":"Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma","volume":"68","author":"Abu-Sbeih","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2022090215583548600_CIT0019","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1002\/cam4.2397","article-title":"Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control","volume":"8","author":"Hughes","year":"2019","journal-title":"Cancer Med"},{"key":"2022090215583548600_CIT0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2217\/imt-2018-0146","article-title":"Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-iv melanoma patients","volume":"11","author":"Lang","year":"2019","journal-title":"Immunotherapy"},{"key":"2022090215583548600_CIT0021","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022090215583548600_CIT0022","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/CJI.0000000000000383","article-title":"Immune checkpoint inhibitor-associated diarrhea and colitis: a systematic review and meta-analysis of observational studies","volume":"44","author":"Tran","year":"2021","journal-title":"J Immunother"},{"key":"2022090215583548600_CIT0023","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s00262-021-02880-0","article-title":"Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events","volume":"70","author":"Nashed","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2022090215583548600_CIT0024","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022090215583548600_CIT0025","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2022090215583548600_CIT0026","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2022090215583548600_CIT0027","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"2022090215583548600_CIT0028","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?","volume":"123","author":"Cheung","year":"2020","journal-title":"Br J Cancer"},{"key":"2022090215583548600_CIT0029","doi-asserted-by":"crossref","first-page":"e001488","DOI":"10.1136\/jitc-2020-001488","article-title":"Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab","volume":"8","author":"Nahar","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"2022090215583548600_CIT0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2022090215583548600_CIT0031","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/9\/799\/45667828\/oyac108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/9\/799\/45667828\/oyac108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T16:07:23Z","timestamp":1662134843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/9\/799\/6603258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,6,6]]},"published-print":{"date-parts":[[2022,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac108","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,6,6]]}}}